William Blair Issues Positive Forecast for Incyte Earnings

Incyte Co. (NASDAQ:INCY) – Investment analysts at William Blair raised their Q2 2025 earnings estimates for Incyte in a research report issued to clients and investors on Tuesday, March 18th. William Blair analyst M. Phipps now expects that the biopharmaceutical company will earn $1.11 per share for the quarter, up from their prior estimate of $1.10. William Blair currently has a “Market Perform” rating on the stock. The consensus estimate for Incyte’s current full-year earnings is $4.86 per share. William Blair also issued estimates for Incyte’s Q3 2025 earnings at $1.19 EPS and Q3 2026 earnings at $1.30 EPS.

Several other research firms have also recently commented on INCY. Citigroup lowered their target price on shares of Incyte from $97.00 to $88.00 and set a “buy” rating on the stock in a research note on Tuesday, February 11th. Wells Fargo & Company raised their target price on shares of Incyte from $68.00 to $70.00 and gave the company an “equal weight” rating in a research note on Thursday, December 19th. UBS Group initiated coverage on shares of Incyte in a research note on Tuesday, December 17th. They set a “neutral” rating and a $77.00 target price on the stock. Stifel Nicolaus raised their price objective on shares of Incyte from $75.00 to $77.00 and gave the company a “hold” rating in a research report on Monday, February 10th. Finally, StockNews.com lowered shares of Incyte from a “strong-buy” rating to a “buy” rating in a research report on Wednesday, February 12th. One research analyst has rated the stock with a sell rating, thirteen have issued a hold rating and six have assigned a buy rating to the company’s stock. According to MarketBeat.com, Incyte currently has an average rating of “Hold” and a consensus target price of $75.13.

Incyte Stock Up 0.4 %

Incyte stock opened at $60.58 on Thursday. The stock has a market cap of $11.72 billion, a price-to-earnings ratio of 224.38, a PEG ratio of 0.41 and a beta of 0.76. The company has a current ratio of 1.97, a quick ratio of 1.94 and a debt-to-equity ratio of 0.01. The company’s 50-day moving average price is $70.78 and its two-hundred day moving average price is $70.13. Incyte has a 52 week low of $50.35 and a 52 week high of $83.95.

Incyte (NASDAQ:INCY) last released its quarterly earnings data on Monday, February 10th. The biopharmaceutical company reported $1.09 earnings per share for the quarter, missing analysts’ consensus estimates of $1.57 by ($0.48). Incyte had a return on equity of 0.05% and a net margin of 0.77%.

Insider Buying and Selling

In related news, EVP Steven H. Stein sold 12,352 shares of the firm’s stock in a transaction that occurred on Tuesday, January 21st. The shares were sold at an average price of $72.69, for a total transaction of $897,866.88. Following the completion of the sale, the executive vice president now directly owns 66,967 shares in the company, valued at approximately $4,867,831.23. This trade represents a 15.57 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, EVP Sheila A. Denton sold 599 shares of the business’s stock in a transaction that occurred on Tuesday, March 4th. The shares were sold at an average price of $69.99, for a total transaction of $41,924.01. Following the transaction, the executive vice president now directly owns 25,848 shares in the company, valued at $1,809,101.52. The trade was a 2.26 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders sold 46,827 shares of company stock valued at $3,322,618. Corporate insiders own 17.60% of the company’s stock.

Institutional Investors Weigh In On Incyte

A number of institutional investors have recently modified their holdings of INCY. Quintet Private Bank Europe S.A. acquired a new position in shares of Incyte in the fourth quarter worth $26,000. Global X Japan Co. Ltd. increased its stake in shares of Incyte by 144.7% in the fourth quarter. Global X Japan Co. Ltd. now owns 389 shares of the biopharmaceutical company’s stock worth $27,000 after acquiring an additional 230 shares during the last quarter. Brooklyn Investment Group acquired a new position in shares of Incyte in the third quarter worth $30,000. R Squared Ltd acquired a new position in shares of Incyte in the fourth quarter worth $30,000. Finally, Point72 Asia Singapore Pte. Ltd. acquired a new position in shares of Incyte in the third quarter worth $33,000. Institutional investors and hedge funds own 96.97% of the company’s stock.

About Incyte

Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics for hematology/oncology, and inflammation and autoimmunity areas in the United States and internationally. The company offers JAKAFI (ruxolitinib) for treatment of intermediate or high-risk myelofibrosis, polycythemia vera, and steroid-refractory acute graft-versus-host disease; MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab) for relapsed or refractory diffuse large B-cell lymphoma; PEMAZYRE (pemigatinib), a fibroblast growth factor receptor kinase inhibitor that act as oncogenic drivers in liquid and solid tumor types; ICLUSIG (ponatinib) to treat chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia; and ZYNYZ (retifanlimab-dlwr) to treat adults with metastatic or recurrent locally advanced Merkel cell carcinoma, as well as OPZELURA cream for treatment of atopic dermatitis.